Enjoy complimentary customisation on priority with our Enterprise License!
The sequencing reagents market size is forecast to increase by USD 4.11 billion, at a CAGR of 12.4% between 2023 and 2028. The market is witnessing significant growth due to the increasing importance of genomic information science in various sectors, particularly in human health. With the completion of the human genome project, genome mapping and sequencing have become essential tools in understanding genome positions and their roles in diseases, including metastatic breast cancer. The advances in genome sequencing technology, such as next-generation sequencing techniques, have made it more accessible and affordable for researchers and healthcare providers. However, there are still challenges, including the need for advanced bioinformatics tools to analyze the vast amounts of data generated from genome sequencing. Additionally, inadequate resources for DNA sequencing in developing countries present an opportunity for market growth. As cancer diagnosis and treatment continue to rely on genomic information, the market is expected to expand.
The market is witnessing significant growth due to the increasing demand for genomic analysis in various sectors, including drug discovery, gene therapy, molecular diagnostics, and genomic medicine. This market is driven by the need for accurate and efficient sequencing tests to identify genetic variants, DNA methylation, gene expression profiling, and biomarker discovery. Genomic analysis plays a crucial role in disease risk assessment, disease movement, genome-wide association studies, and precision medicine. The application of sequencing reagents in cancer immunotherapy, genome interpretation, and disease prediction is also gaining popularity. Liquid biopsy, a minimally invasive diagnostic approach, is another area where sequencing reagents are extensively used. The biotechnology industry is at the forefront of innovation in the field of genomic analysis. Technological advancements in RNA sequencing, genomic data analysis, and genome information have led to the development of next-generation sequencing (NGS) technologies. These technologies enable high-throughput sequencing, which is essential for population genomics and clinical genomics. The market is expected to grow as the use of genomic data in healthcare innovation continues to expand. Gene editing, personalized medicine, genetic counseling, and synthetic biology are some of the emerging areas where sequencing reagents are finding applications. Data processing and genome analysis are critical components of the sequencing workflow.
The market is driven by the need for accurate and efficient sequencing tests to identify genetic variants, DNA methylation, gene expression profiling, and biomarker discovery. The use of sequencing reagents in drug discovery, gene therapy, molecular diagnostics, and genomic medicine is expected to continue to grow, providing opportunities for market participants. In conclusion, the market is a dynamic and growing market, driven by the increasing demand for genomic analysis in various sectors. The market is expected to continue to grow as the use of genomic data in healthcare innovation expands. The accuracy and reliability of sequencing reagents are essential to ensure the quality of genomic data and drive the demand for these reagents. The market is expected to provide opportunities for participants as the use of sequencing reagents in drug discovery, gene therapy, molecular diagnostics, and genomic medicine continues to grow.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
The next-generation sequencing segment is estimated to witness significant growth during the forecast period. The market is experiencing significant growth due to the increasing demand for next-generation sequencing (NGS) technologies in various sectors, including human genome research, genomic information science, and healthcare. NGS technologies, such as Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, and Nanopore Sequencing, are transforming the market with their advanced capabilities and broad applications. These technologies offer high throughput, scalability, and speed, making them essential for clinical diagnostics, drug discovery, and personalized medicine.
Get a glance at the market share of various segments Download the PDF Sample
The next-generation sequencing segment was valued at USD 1.80 billion in 2018. SBS technology, a type of NGS, is the most widely used due to its high accuracy and ability to generate large volumes of data. Leading companies, such as Illumina, have pioneered this technology, providing comprehensive solutions that include reagents, instruments, and software. In the healthcare sector, NGS technologies are being used to diagnose and treat conditions like metastatic breast cancer by identifying genome positions associated with the disease. Bioinformatics tools are used to analyze the genomic data, aiding in cancer diagnosis and treatment. The science of genomics continues to evolve, and the market is poised to grow as these technologies become more accessible and affordable.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 39% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. In North America, the market holds a substantial share due to the region's advanced research infrastructure, substantial funding, and technological innovations. The United States is a significant contributor to this market's growth. Extensive research funding from both government and private sectors, such as the National Institutes of Health (NIH) investments in genomic research, drives the demand for sequencing reagents in applications like clinical diagnostics, oncology, and personalized medicine. Furthermore, the presence of prominent life sciences companies, including Illumina and Thermo Fisher Scientific, bolsters the market's strength. Fluorescent dyes and modified nucleotides are essential reagents in genomic medicine, enabling the acquisition of functional information from sequencing projects.
These reagents play a crucial role in the identification of disease characteristics and the development of targeted therapies. As sequencing costs decrease, the demand for these reagents is expected to increase, leading to potential growth opportunities for reagent manufacturers. Effective data storage and management systems are also essential for handling the massive amounts of data generated during sequencing projects. Overall, the North American market is poised for continued growth due to these factors.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The increasing affordability of DNA sequencing is notably driving market growth. The market has experienced a notable reduction in the expense of DNA sequencing as a result of technological innovations. For example, the National Human Genome Research Institute (NHGRI) in the US reports that the cost of sequencing one million bases of DNA dropped from approximately USD 1,000 in 2004 to a mere penny in 2019. The NHGRI has amassed extensive data on DNA sequencing costs over the years through the institute-funded sequencing centers. This data, analyzed and compiled by the NHGRI, provides valuable insights into the advancements in DNA sequencing technologies. Cost reduction in DNA sequencing has significant implications for tailored medical treatments, particularly for chronic illnesses and drug-resistant conditions such as tuberculosis (TB). Molecular diagnostics, which rely on sequencing techniques, are becoming increasingly important in the identification and treatment of these conditions. Array-based technologies, rapid exome sequencing, and ultra-rapid genome sequencing are some of the techniques driving this trend.
In addition, the market is witnessing a significant drop in costs, which is leading to increased adoption in various applications, particularly in healthcare and bio-pharmaceuticals. This trend is expected to continue as technological advances continue to drive down costs and improve the speed and accuracy of sequencing techniques. The potential for personalized treatments and the development of new drugs are key drivers of market growth. Thus, such factors are driving the growth of the market during the forecast period.
Advances in next generation sequencing techniques is the key trend in the market. Next-generation sequencing (NGS) technology has revolutionized the field of DNA sequencing by enabling the rapid and cost-effective arrangement of DNA at a scale never before possible. The Human Genome Project (HGP), initiated in 1990, laid the groundwork for this innovation, providing a comprehensive understanding of the human genome's structure and function. NGS technology has since found applications in various clinical settings, particularly in the diagnosis and treatment of diseases such as cancer. By identifying genetic variations, researchers and medical practitioners can develop companion diagnostics and personalized treatment plans for patients. The cost reduction of sequencing reagents, a crucial component of NGS, has made this technology accessible to a broader range of laboratories. This affordability has led to increased adoption and innovation in the field, contributing to advancements in chronic disease research and oncology.
As a result, the application of NGS technology continues to expand, providing valuable insights into the genetic basis of various diseases and contributing to the development of new therapeutic approaches. In summary, the advent of NGS technology and the Human Genome Project have paved the way for significant advancements in the field of genomics. The reduction in the cost of sequencing reagents and the availability of open-source licenses have made this technology accessible to a broader range of researchers and medical practitioners, leading to new discoveries and innovative applications in various clinical environments. Thus, such trends will shape the growth of the market during the forecast period.
Inadequate resources for DNA sequencing in developing countries is the major challenge that affects the growth of the market. The field of genome sequencing has witnessed substantial advancements, leading to enhanced investigative accuracy and decreased costs. Consequently, the utilization of genome sequencing has broadened, with applications ranging from economic genome sequencing in research institutions to intensive care units for diagnostic studies. However, developing countries face challenges in fully leveraging genome sequencing due to limited funding. This lack of funding can be attributed to several factors, including a shortage of skilled personnel, the high costs of establishing and maintaining sequencing facilities, the inconsistency of outsourcing services, and restricted access to essential tools, such as sequencing reagents, for genomic data analysis and manipulation.
For instance, the cost of analyzing a sequencing platform can reach nearly USD 100,000, while a single sequencing reaction may cost over USD 1,000 per genome. In the market, third-generation sequencing technologies, including single-molecule real-time and oxford nanopore sequencer, are gaining popularity for their ability to generate longer reads and higher genome sequencing accuracy, thereby enhancing the diagnostic value of genomic surveillance in various sectors, including in-vitro diagnostics and pathology. Hence, the above factors will impede the growth of the market during the forecast period.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Roche.com - The company offers sarcoma therapeutics products under the brand name of Tibsovo.
The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market is a significant segment of the life sciences industry, fueled by the advancements in DNA sequencing technology. Sequencing reagents play a crucial role in the process of DNA sequencing, enabling the arrangement of nucleotides in their correct order to decipher the genetic information contained within DNA sequences. Next-generation sequencing (NGS) technologies, such as nanopores and single-molecule real-time, have revolutionized the field of genomic information science by offering ultra-rapid genome sequencing and reduced costs. These advancements have opened up new opportunities in various sectors, including oncology, chronic diseases, and molecular diagnostics. Reagent manufacturers continue to innovate, developing modified nucleotides and fluorescent dyes to improve sequencing accuracy and efficiency. The cost structure of sequencing projects includes both direct costs, such as reagent expenses, and indirect charges, such as license fees and data storage.
Moreover, the application of genomic data science in areas like cancer diagnosis and treatment, drug-resistant TB, and genomic surveillance in intensive care units, has led to tailored medical treatments based on an individual's genetic makeup. The use of open-source licenses and array-based technologies has further accelerated research in genomic medicine. The bio-pharmaceutical expenditure on genomic research and development is expected to grow as the importance of genomic information in understanding disease characteristics and developing targeted therapies becomes increasingly recognized. The future of the market lies in the continued innovation and integration of these technologies into various industries and applications.
Market Scope |
|
Report Coverage |
Details |
Page number |
165 |
Base year |
2023 |
Historic period |
2018 - 2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 12.4% |
Market Growth 2024-2028 |
USD 4.11 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
10.6 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 39% |
Key countries |
US, Canada, Germany, UK, China, France, Italy, Japan, India, and South Korea |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Agilent Technologies Inc., BGI Group, BioChain Institute Inc., F. Hoffmann La Roche Ltd., Fluidigm Corp., FroggaBio Inc., Illumina Inc., LGC Biosearch Technologies, Merck KGaA, Meridian Bioscience Inc, New England Biolabs Inc., Oxford Nanopore Technologies plc, Pacific Biosciences of California Inc., Perkin Elmer Inc., QIAGEN N.V., Takara Bio Inc., Tecan Trading AG, Thermo Fisher Scientific Inc., and Trilink Biotechnologies |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for market forecast period. |
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements.
1 Executive Summary
2 Technavio Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Technology
9 Customer Landscape
10 Geographic Landscape
11 Drivers, Challenges, and Opportunity/Restraints
12 Competitive Landscape
13 Competitive Analysis
14 Appendix
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Get the report (PDF) sent to your email within minutes.
Complimentary full Excel data with your report purchase.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.